Belluscura (BELL FOLLOW ) has appointed Brian Brown, who has over 25 years of experience in commercialising break-through new products, as its new Vice President of Engineering.
Belluscura, a medical device developer which is focused on developing lightweight and portable oxygen enrichment technology, said Mr Brown’s extensive knowledge in building a start-up medical device company will add to the company’s experienced management team.
Brown, who has over 25 years of experience in commercialising new products in hardware, software, and service delivery industries, built the start-up into a global supplier of diagnostic imaging medical devices where he held the titles of President and Chief Innovation Officer.
Brown, who is also a registered professional engineer and is the author of 17 US patents, stated: “It’s exciting to be part of a very talented Belluscura team. I look forward to helping Belluscura launch its breakthrough new technologies and change the face of patient care.”
Robert Rauker, CEO of Belluscura added: “We look forward to leveraging Brian’s background in new product commercialization. His knowledge in building a start-up medical device firm will add to our experienced management team. We’re excited to have Brian on board.”
In recent weeks, Belluscura announced that it had signed a new agreement with InnoMax Medical Technology that is expected to more than double its manufacturing capacity of its X-PLO2R® portable oxygen concentrator and accelerate its expansion into Asia and beyond.
The commercialisation and distribution in Asia are expected to occur no later than 1Q23 and Belluscura intends to manufacture both the company’s next generation X-PLO2R® oxygen concentrator and the next portable oxygen concentrator in its portfolio, the DISCOV-R™.
Belluscura’s devices are designed to address a market need: According to the World Health Organisation (“WHO”), over 1 billion people in the world suffer from chronic respiratory issues.
Overall, the global oxygen therapy market size is expected to grow at a significant CAGR of 10.12% from 2021 to 2026 to be worth $18.55 billion by 2026. The global portable oxygen concentrators market is forecast to be worth $2.76 billion by 2026 - that’s a CAGR of 14%.
In China alone, nearly 100 million people suffer from chronic obstructive pulmonary disease (“COPD”). This is 400% larger than the total US COPD population, and it is estimated to be the third leading cause of death in China.
Beyond this market, there are an estimated 50 million cases of COPD in India and over 5 million people in Japan suffering from COPD.
Follow News & Updates from Belluscura : FOLLOW
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
See Today's Market Movers featuring ThinkSmart Limited, Tower Resources, Sabien Technology Group and Condor Gold
(Sharecast News) - London stocks finished a turbulent week in the green on Friday, recovering from heavy losses earlier in the week as consternation over inflation and a slowdown in global growth rattled markets.
Stocks mentioned include: #BELL #REVB #MBH #VRCI #FDP #TRU #SAL #IFX.DE #TRLS #BOO #AMYT
Today, Sabien Technology Group has acknowledged the announcements from the UK and Welsh Governments committing to helping clear a new industrial site in Anglesey, Wales.
Zak Mir charts DeepVerge, East Imperial, HeliumOne, Made, Mode, Powerhouse, Pantheon, Quadrise and Audioboom.
Russ Mould, Investment Director at stockbroker AJ Bell asks the question: one stablecoin has been found out, which one is next? This follows volatility in the crypto market this week that centred around the demise of Terra (LUNA) which collapsed by more than 99%, wiping out the fortunes of crypto investors. LUNA has been compounded by issues with Terra’s dollar-pegged stablecoin UST.
Sarah Willingham of Nightcap #NGHT discusses their impressive growth, where net sales for 40 weeks ended 3 April 2022 increased by 24.4% to £25.2m on like for like basis compared to 2019, and also talks about their new site openings and additional pipeline.
Despite capital almost drying up across the IPO/secondary market, the very best investment opportunities still attract money. Take Belluscura - a next generation medical devices firm specialising in portable & light weight oxygen concentrators (POCs) - used to treat patients with severe respiratory conditions, such as COPD (chronic obstructive pulmonary disease), pneumonia & potentially long COVID too.
Downing Renewables & Infrastructure Trust said its unaudited NAV was £150.9m or 110.1 pence per share as at 31 March 2022 - an increase of 6.4% from the previous quarter amid accretive acquisitions, increasing power prices, inflation and a solid financial performance.
Zephyr Energy CEO, Colin Harrington, answers investors questions covering drilling programs , crypto mining and and expected newsflow.